Skip to main content

Table 3 Logistic regression analyses of clinicopathologic factors and AI-analyzed image data impacting PDX engraftment

From: Factors associated with engraftment success of patient-derived xenografts of breast cancer

  

All (n = 320)

Univariate **

(Odds ratio, 95% CI, p-value***)

Multivariate **

(Odds ratio, 95% CI, p-value***)

  

NAC group (n = 131)

Univariate **

(Odds ratio, 95% CI, p-value***)

Multivariate**

(Odds ratio, 95% CI, p-value***)

Variable*

 

Failure (n = 270)

Success (n = 50)

  

Variable*

 

Failure (n = 93)

Success (n = 38)

  

AP

Mean ± SD

639.9 ± 727.1

409.0 ± 484.0

0.61 (0.47–0.79, p = 0.035)

 

AP

Mean ± SD

517.3 ± 622.2

450.9 ± 528.0

0.82 (0.74–0.91, p = 0.562)

 

NP

Mean ± SD

740.7 ± 981.9

1575.0 ± 1264.1

1.58 (1.39–1.80, p < 0.001)

1.927 (1.077–3.449, p = 0.027)

NP

Mean ± SD

901.3 ± 1101.4

1642.8 ± 1358.9

1.60 (1.38–1.85, p = 0.003)

 

TDLUP

Mean ± SD

504.4 ± 692.5

219.8 ± 233.3

0.18 (0.08–0.41, p = 0.006)

 

TDLUP

Mean ± SD

475.2 ± 730.2

201.6 ± 213.9

0.22 (0.18–0.27, p = 0.034)

0.181 (0.033–1.00, p = 0.06)

SP

Mean ± SD

3377.5 ± 1265.9

2855.3 ± 1094.8

0.63 (0.46–0.86, p = 0.007)

1.545 (0.844–2.827, p = 0.159)

SP

Mean ± SD

3512.4 ± 1523.4

2855.7 ± 1180.3

0.71 (0.60–0.84, p = 0.022)

 

TILP

Mean ± SD

17.8 ± 22.8

15.0 ± 15.9

0.00 (0–7833.4, p = 0.401)

 

TILP

Mean ± SD

10.2 ± 14.0

11.3 ± 13.3

283.00 (29.48–2718.95, p = 0.676)

 

ICP

Mean ± SD

4208.0 ± 1450.8

4571.6 ± 1201.5

1.19 (0.97–1.45, p = 0.097)

1.820 (1.028–3.223, p = 0.040)

ICP

Mean ± SD

4105.8 ± 1552.8

4505.6 ± 1187.3

1.00 (1.00–1.00, p = 0.159)

 

Age

Mean ± SD

50.9 ± 12.1

45.6 ± 10.4

0.96 (0.94–0.99, p = 0.005)

0.96 (0.92–1.00, p = 0.032)

Age

Mean ± SD

49.6 ± 10.3

45.6 ± 11.0

0.96 (0.93–1.00, p = 0.053)

 

Ki-67LI (%)

Mean ± SD

41.2 ± 28.7

74.0 ± 14.3

1.06 (1.04–1.08, p < 0.001)

1.05 (1.02–1.07, p < 0.001)

Ki-67LI (%)

Mean ± SD

39.2 ± 32.5

75.0 ± 14.3

1.06 (1.03–1.09, p < 0.001)

1.07 (1.03–1.10, p < 0.001)

Subtype

HER2 + 

20 (7.4%)

1 (2%)

  

Subtype

HER2 + 

8 (8.6%)

1 (2.6%)

  
 

HR + 

130 (48.1%)

4 (8%)

0.62 (0.07–5.79, p = 0.671)

  

HR + 

35 (37.6%)

3 (7.9%)

0.69 (0.06–7.48, p = 0.757)

 
 

HR + /HER2 + 

30 (11.1%)

1 (2%)

0.67 (0.04–11.29, p = 0.779)

  

HR + /HER2 + 

14 (15.1%)

1 (2.6%)

0.57 (0.03–10.43, p = 0.706)

 
 

TNBC

90 (33.3%)

44 (88%)

9.78 (1.27–75.23, p = 0.028)

  

TNBC

36 (38.7%)

33 (86.8%)

7.33 (0.87–61.82, p = 0.067)

 

Diagnosis

IDC

250 (92.6%)

45 (90%)

  

Diagnosis

IDC

87 (93.5%)

34 (89.5%)

  
 

Other

20 (7.4%)

5 (10%)

1.39 (0.50–3.89, p = 0.532)

  

Other

6 (6.5%)

4 (10.5%)

1.71 (0.45–6.42, p = 0.430)

 

HG

2

139 (51.5%)

3 (6%)

  

HG

2

41 (44.1%)

3 (7.9%)

  
 

3

131 (48.5%)

47 (94%)

16.62 (5.05–54.71, p < 0.001)

4.34 (1.08–17.53, p = 0.039)

 

3

52 (55.9%)

35 (92.1%)

9.20 (2.64–32.05, p < 0.001)

 

NAC

No

177 (65.6%)

12 (24%)

  

Miller-Payne grade

Mean ± SD

2.3 ± 0.8

1.6 ± 0.8

0.34 (0.20–0.57, p < 0.001)

0.30 (0.16–0.58, p < 0.001)

 

Yes

93 (34.4%)

38 (76%)

6.03 (3.01–12.09, p < 0.001)

3.27 (1.41–7.60, p = 0.006)

RCB score

Mean ± SD

3.1 ± 1.0

3.4 ± 1.2

1.24 (0.86–1.78, p = 0.253)

 

Size (cm)

Mean ± SD

3.1 ± 2.0

4.4 ± 2.8

1.23 (1.09–1.38, p < 0.001)

1.20 (1.02–1.41, p = 0.029)

Size (cm)

Mean ± SD

4.0 ± 2.6

5.0 ± 2.9

1.13 (0.99–1.30, p = 0.064)

 

LVI

No

151 (55.9%)

30 (60%)

  

LVI

No

44 (47.3%)

21 (55.3%)

  
 

Yes

119 (44.1%)

20 (40%)

0.85 (0.46–1.56, p = 0.594)

  

Yes

49 (52.7%)

17 (44.7%)

0.73 (0.34–1.55, p = 0.410)

 

Metastatic LNs

Mean ± SD

2.1 ± 5.8

4.5 ± 9.5

1.04 (1.00–1.08, p = 0.031)

 

Metastatic LNs

Mean ± SD

4.1 ± 8.9

5.8 ± 10.6

1.02 (0.98–1.06, p = 0.350)

 

TIL (%)

Mean ± SD

12.0 ± 18.4

9.4 ± 13.8

0.99 (0.97–1.01, p = 0.351)

 

TIL (%)

Mean ± SD

6.1 ± 11.6

6.3 ± 8.5

1.00 (0.97–1.04, p = 0.928)

 
  1. AP Adipose proportion, NP Necrosis proportion, BP Background proportion, TDLUP Terminal ductal lobular unit proportion, SP Stroma proportion, TILP Tumor-infiltrating lymphocyte proportion, ICP Invasive carcinoma proportion, Ki-67LI Ki-67 labeling index, HR + Hormone receptor-positive breast cancer, TNBC Triple-negative breast cancer, HR + /HER2 + Hormone receptor and HER2 positive breast cancer, HER2 + HER2 positive breast cancer, IDC Invasive ductal carcinoma, HG Histologic grade, NAC Neoadjuvant chemotherapy, LVI Lymphovascular invasion, LN Lymph node, TIL Tumor infiltrating lymphocytes
  2. *AP, BP, NP, TDLUP, SP, TILP, ICP values scaled up by 10,000
  3. **AP, BP, NP, TDLUP, SP, TILP, ICP: OR calculated with 1,000-unit change, corresponding to 0.1% of intratumoral percentage adjustment
  4. ***Bold: significant at p-value < 0.05